Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies.
Many broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus type 1 (HIV-1) were shown effective in animal models, and are currently evaluated in clinical trials. However, use of these antibodies in humans is hampered by the rapid emergence of resistant viruses. Here we show tha...
Main Authors: | Yuka Otsuka, Kimberly Schmitt, Brian D Quinlan, Matthew R Gardner, Barnett Alfant, Adrian Reich, Michael Farzan, Hyeryun Choe |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-08-01
|
Series: | PLoS Pathogens |
Online Access: | http://europepmc.org/articles/PMC6117093?pdf=render |
Similar Items
-
Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
by: Lynch RM, et al.
Published: (2012-09-01) -
HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
by: Labranche, CC, et al.
Published: (2018) -
HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2018-11-01) -
Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2019-03-01) -
Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01
by: E. Fabian Cardozo-Ojeda, et al.
Published: (2021-08-01)